Supplementary Materials

Supplementary Material for:

Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination

Nicole L. Yates, Hua-Xin Liao, Youyi Fong, Allan deCamp, Nathan A. Vandergrift, William T. Williams, S. Munir Alam, Guido Ferrari, Zhi-yong Yang, Kelly E. Seaton, Phillip W. Berman, Michael D. Alpert, David T. Evans, Robert J. O'Connell, Donald Francis, Faruk Sinangil, Carter Lee, Sorachai Nitayaphan, Supachai Rerks-Ngarm, Jaranit Kaewkungwal, Punnee Pitisuttithum, James Tartaglia, Abraham Pinter, Susan Zolla-Pazner, Peter B. Gilbert, Gary J. Nabel, Nelson L. Michael, Jerome H. Kim, David C. Montefiori, Barton F. Haynes, Georgia D. Tomaras*

*Corresponding author. E-mail: gdt@duke.edu

Published 19 March 2014, Sci. Transl. Med. 6, 228ra39 (2014)
DOI: 10.1126/scitranslmed.3007730

This PDF file includes:

  • Fig. S1. Significant correlation of Env IgG3 and V1-V2 with ADCC in RV144, but not VAX003.
  • Fig. S2. Lack of direct correlations for all HIV-1 Env IgG1 and IgG3 antibody responses.
  • Fig. S3. Weak association between V1-V2 IgG and V1-V2 IgG3 measurements.
  • Fig. S4. Cumulative incidence plots of IgG3 to V1-V2 antigens in an RV144 case-control analysis.
  • Fig. S5. Vaccination scheme for RV144 (top) and VAX003 (bottom) vaccine regimens.
  • Table S1. ORs for HIV-1 infection risk in univariate analyses of IgG3 measurements.
  • Table S2. HIV-1 Env IgG4 response rates in RV144 vaccinees do not decline between peak immunogenicity (week 26) and week 52

[Download PDF]